Stock fact sheet · data as of
Nurix Therapeutics, Inc. (NRIX): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Value
Is NRIX undervalued?
NRIX has a margin of safety of 32%: the stock closed at 24.95 on 16 Oct 2026 against a GLS average fair value of 36.95. 4 of the 7 valuation models that produced a number sit above the price. Our screens treat a discount this large as a strong starting point for a cash-secured put, not as a verdict - the fair value is a model output, and a wide gap can mean the models are missing something the market knows.
There is a wide gap between GLS Growth (7.91) and 10 Cap (69.20). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files NRIX under Value: positive earnings at a P/E of 18 or less.
Nine valuation models for NRIX
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 22.72 | -9% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 50.92 | +104% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 14.80 | -41% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 7.91 | -68% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 69.20 | +177% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 63.71 | +155% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 29.37 | +18% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 4.41 | -82% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 35.42 | +42% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Nurix Therapeutics, Inc. scores 7 of 9 on the Piotroski F-score, the nine yes/no tests of profitability, leverage and efficiency on the latest annual accounts - a strong reading that passes the Sunday Scan's "6 or more" rule with room to spare. A GLS Moat score of 2.5/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -44.5%, ROE -49.1%, ROA -38.4% - with debt at 0.10 times equity and a free-cash-flow yield of 14.3%.
Nurix Therapeutics, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Collaboration Revenue 100% (quarter Q2 FY2026).
Institutional ownership scores 10/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 7 / 9 | ROIC | -44.5% |
|---|---|---|---|
| GLS Moat | 2.5 / 10 | ROE | -49.1% |
| Debt / equity | 0.10 | ROA | -38.4% |
| Free-cash-flow yield | 14.3% | Payout ratio | 0% |
| Institutions | 10 / 10 | Insiders · Congress | 1 · 5 / 10 |
Wheel Score 74: Good
With a Wheel Score of 74 - the Good band - Nurix Therapeutics, Inc. clears the Sunday Scan's "70 or higher" rule. The parts: Value 25/25, Health 16/20, Moat 4/15, Premium 14/20, Stability 16/20; Moat (4/15) scores lowest.
Implied volatility is 83% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (14 of 20) because volatility this high usually comes with a reason. Chain open interest is 6,581 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 3.3M shares a day on a market cap of $2.6B, with a beta of 1.82 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 16 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 32% margin of safety | |
| Health | 16 / 20 | Piotroski 7/9 | |
| Moat | 4 / 15 | moat 2.5/10 | |
| Premium | 14 / 20 | implied volatility 83% | |
| Stability | 16 / 20 | 3.3M shares/day, $2.6B cap, beta 1.82 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for NRIX in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Nurix Therapeutics, Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| BEAM Beam Therapeutics Inc. | 24.73 | - | - | 45Weak | $2.6B |
| PGEN Precigen, Inc. | 7.36 | - | - | 45Weak | $2.6B |
| ZLAB Zai Lab Limited | 22.50 | - | - | 45Weak | $2.5B |
| MBX MBX Biosciences, Inc. Common Stock | 50.71 | 2.02 | -2406% | 28Weak | $2.4B |
| NAMS NewAmsterdam Pharma Company N.V. | 20.62 | 3.67 | -462% | 37Weak | $2.4B |
| ADMA ADMA Biologics, Inc. | 10.73 | 21.14 | +49% | 79Good | $2.4B |
| SLS SELLAS Life Sciences Group, Inc. | 11.88 | 0.6270 | -1795% | 25Weak | $2.4B |
| RCUS Arcus Biosciences, Inc. | 22.53 | - | - | 39Weak | $2.8B |
| DYN Dyne Therapeutics, Inc. | 15.29 | 6.74 | -127% | 41Weak | $2.9B |
| ELVN Enliven Therapeutics, Inc. | 39.33 | 1.70 | -2210% | 44Weak | $2.9B |
| DNLI Denali Therapeutics Inc. | 18.34 | 0.9548 | -1821% | 38Weak | $2.9B |
| CELC Celcuity Inc. | 60.30 | - | - | 45Weak | $3.0B |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about NRIX
Is NRIX undervalued right now?
By the GLS models, yes: at 24.95 the stock is 32% below the average fair value of 36.95 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of NRIX and what does it mean?
NRIX scores 74 out of 100 (Good). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for NRIX?
36.95 per share as of 16 Oct 2026 - the simple average of the 7 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Nurix Therapeutics, Inc. report earnings next?
No upcoming earnings date is recorded for NRIX in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.
Does NRIX have listed options, and how liquid are they?
Yes. The nightly snapshot found 240 listed contracts with 6,581 open interest across all expiries and implied volatility of 83% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.